Effect of esomeprazole versus placebo on pulmonary exacerbations in cystic fibrosis.

ABSTRACT:

Background

Gastro esophageal reflux (GER) is common in cystic fibrosis (CF) and may contribute to lung disease. Approximately 50% of patients with cystic fibrosis are being treated with proton pump inhibitors (PPIs).

Methods

In a randomized controlled study in adults, we compared treatment with esomeprazole 40 mg twice daily versus placebo in patients with CF and frequent respiratory exacerbations over a thirty-six week treatment period to determine effect on time to first exacerbation and other health related outcomes.

Results

17 patients without symptoms of GER were randomized and 15 completed the study. 13 subjects underwent 24 hour ambulatory pH probe monitoring; 62% had pH probe evidence of GER. Forty one percent of subjects had a pulmonary exacerbation during th

SUBMITTER: Dimango E 

PROVIDER: S-EPMC3931289 | biostudies-literature | 2014 Feb

REPOSITORIES: biostudies-literature